Cilengitide

Catalog No.S7077

Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.

Price Stock Quantity  
USD 454 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Cilengitide Chemical Structure

Cilengitide Chemical Structure
Molecular Weight: 702.68

Validation & Quality Control

Customer Product Validation(3)

Quality Control & MSDS

Product Information

  • Compare Integrin Inhibitors
    Compare Integrin Products
  • Research Area

Product Description

Biological Activity

Description Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.
Targets αvβ3 receptor [1]
(Cell-free assay)
αvβ5 receptor [2]
(Cell-free assay)
IC50 4.1 nM 79 nM
In vitro Cilengitide is a cyclized pentapeptide peptidomimetic designed to compete for the arginine-glycine-aspartic acid (RGD) peptide sequence that regulates integrin-ligand binding. Cilengitide selectively and potently blocks the ligation of theαvβ3 andαvβ5 integrins to provisional matrix proteins such as vitronectin, fibronectin, fibrinogen, von Willebrand factor, osteopontin, and others. [1] Cilegitide inhibits angiogenesis in vitro. 10 μM Cilengitide completely inhibits attachment of BAE, BME and HUVE cells on vitronectin and fibronectin. Cilengitide inhibits in vitro angiogenesis of BAE cells on three-dimensional collagen and fibrin gels pretreated with FGF-2(or VEGF-A) with IC50 of 15 μM and 8 μM, 4 μM and 3 μM, respectively. [2] Cilengitide blocks proliferation and induces apoptosis of endothelial cells as well as differentiation of human endothelial precursor cells (EPCs). 50 μg/mL Cilengitide completely inhibits the proliferation of human microvascular endothelial cell line HMEC-1 and leads to apoptosis in ~30% cells. [3] 1.0 μM Cilengitide treating for 9 days inhibits the proliferation of EPCs by nearly 40%. 1 μM Cilengitide inhibits the differentiation of EPCs by more than 80% at 14 days. [4] Cilengitide inhibits adhesion and induces apoptosis of tumor cells. 25 μg/mL Cilengitide causes detachment of DAOY cells (medulloblastoma) and U87MG cells (glioblastoma) from vitronectin and tenascin by more than 60%. 25 μg/mL Cilengitide induces a nearly 50% apoptosis rate of these cells. [5]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
LN-308 NV\4bWVtTnWwY4Tpc44hSXO|YYm=NGnybo8yNzFyL{GwNQKBkc7:bR?=NFHRcYszPCCqNH;JUpVFVVORwrC=NHG5UI1z\WS3Y3XzJGRTTSC{ZYDvdpRmeiCjY4Tpeol1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>?NVy3[mxSOjZ3MECwOVY>
ZH-161NW[wdYpTTnWwY4Tpc44hSXO|YYm=NULCSWdUOS9zMPMAje69dQ>?NYj1emhMOjRiaB?=M2\nemROW00EoB?=M1rqeJJm\HWlZYOgSHJGKHKncH;yeIVzKGGldHn2bZR6MUOyOlUxODB3Nh?=
S-24MV3GeY5kfGmxbjDBd5NigQ>?NYe2ToNXOS9zMPMAje69dQ>?MkGzNlQhcA>?MWLEUXNQyqB?M4jJUZJm\HWlZYOgSHJGKHKncH;yeIVzKGGldHn2bZR6MXyyOlUxODB3Nh?=
HaCaT M{TDW2Z2dmO2aX;uJGF{e2G7NUPBdHNVOTEkgJpOwI0>MmDwOFghcA>?NWfCUYU3TE2VT9MgM2r5[5Jm\HWlZYOgWGdHNc7{MtMgcXJPSSCneIDy[ZN{cW:wNFPufpczPjVyMEC1Oi=>
LN-308 MWnGeY5kfGmxbjDBd5NigQ>?M1jJ[lEx6oDLzsztNU\4bFdDOjRiaB?=NUXiTYlPTE2VT9MgMn7kdoVlfWOnczDBbHIheHKxdHXpckBt\X[nbIOgZY5lKESURTDy[ZBwenSncjDhZ5Rqfmm2eR?=M1v2VVI3PTByMEW2
RENNWLrPY52S2WubDDWbYFjcWyrdImgRZN{[Xl?MYmxJI5ONTJyMDFOwG0>NHSyOmU4OiCqMlnU[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{NWficId7OjR3OUWyO|Q>
MSTO-211HM{fqd2NmdGxiVnnhZoltcXS7IFHzd4F6MYmxJI5ONTJyMDFOwG0>NH3jVWk4OiCqMV\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?MkDGNlQ2QTV{N{S=
MM05NE\o[JFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?NX\p[2lROSCwTT2yNFAh|ryPMXG3NkBpNHKxNlll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=MXiyOFU6PTJ5NB?=
H28M37QcWNmdGxiVnnhZoltcXS7IFHzd4F6MWSxJI5ONTJyMDFOwG0>M1rlNVczKGh?MmWy[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{NFTjVVIzPDV7NUK3OC=>
SCC25MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3yW2tJPi5{NfMAl|IxOMLiwsXNMY[3NkBpMkS1doV{fWy2czDtc4RmemG2ZTyg[I9{\S2mZYDlcoRmdnRiZ4Lve5RpKGmwaHnibZRqd25?M3e4blI1PTV5MEW2
CAL27NEfScotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fJflYvOjYkgKOyNFDDqML3TR?=NX\1TW9GPzJiaB?=Ml3IdoV{fWy2czDtc4RmemG2ZTyg[I9{\S2mZYDlcoRmdnRiZ4Lve5RpKGmwaHnibZRqd25?NXjrU|B5OjR3NUewOVY>
FaDu MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUS2MlI26oDVMkCwxsDDvU1?NV7iS|ZFPzJiaB?=NYDFRXhlemW|dXz0d{Bud2SncnH0[Uwh\G:|ZT3k[ZBmdmSnboSg[5Jwf3SqIHnubIljcXSrb36=NEHrWXIzPDV3N{C1Oi=>
SCC25M3K5VWFxd3C2b4Ppd{BCe3OjeR?=NFrqdnMzPcLiwsXNxsA>NYfFXW9iPDkEoHlCpC=>M3rJ[Ylv\HWlZYOgZZBweHSxc3nzM{DscVI1PTV5MEW2
CAL27M{nrfmFxd3C2b4Ppd{BCe3OjeR?=MUmyOeKhyrWPwrC=NF3pNWc1QMLiaNMgNXPsWnRYcW6mdXPld{BieG:ydH;zbZM>M2HscVI1PTV5MEW2
FaDu NGHEXJJCeG:ydH;zbZMhSXO|YYm=M3jjS|I2yqEEtV5CpC=>MYm0POKhcMLiNWrYXVhXcW6mdXPld{BieG:ydH;zbZM>MXSyOFU2PzB3Nh?=
T-47DM{K5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmWzNE0zOCEQvF2=MYK5OkBpNUXCUFFLcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?NV7KTZlqOjRzNUOxNFI>
MCF-7 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\SRXYxNTJyIN88US=>NInz[nc6PiCqM2XhTIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzNX\IUoI{OjRzNUOxNFI>
T-47DNXrxU2VuSXCxcITvd4l{KEG|c3H5NXvGeXR7OC1{MDFOwG0>NGC5VIM1QCCqNE\jWm1qdmS3Y3XzJIFxd3C2b4Ppdy=>MVGyOFE2OzFyMh?=
MCF-7 NHK3fopCeG:ydH;zbZMhSXO|YYm=M4\DR|AuOjBizszNNEnaZWc1QCCqNYPmWXBmcW6mdXPld{BieG:ydH;zbZM>M2K5OlI1OTV|MUCy
U87MGM1;uV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3[2XlAuOjVizszNNXXJNXZZOjRxNEigbC=>NVHsPIczcW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVzNVnkNHd3OjN|NUS4NFc>
U251MGMlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWWwMVI2KM7:TR?=M2jNcFI1NzR6IHi=NGDJRVFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>M2DpVVI{OzV2OEC3
U87MGM2Hx[2Fxd3C2b4Ppd{BCe3OjeR?=NIDvXmUyKML3TR?=NIHUd3Y1QCCqMYrpcoR2[2W|IHHwc5B1d3Orcx?=M3vVdlI{OzV2OEC3
U251MGM4Li[mFxd3C2b4Ppd{BCe3OjeR?=MUixJOK2VQ>?NWLueGVQPDhiaB?=MofObY5lfWOnczDhdI9xfG:|aYO=MnfQNlM{PTR6MEe=
U251NUWzc4lNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\lN3UxNTJ3IN88[{9uVA>?MoOwNE01QCCqNUi1Om9WcW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVzNYfpbIVGOjF5OEizOFM>
U87 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XQ[VAuOjVizsznM41NMkPZNE01QCCqMWrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=MmXPNlE4QDh|NEO=
U251M1T6R2Fxd3C2b4Ppd{BCe3OjeR?=NX3TUYlLOjVizsznM41NMmTmNlQwPDhiaB?=NES5TnJqdmS3Y3XzJIFxd3C2b4Ppd{BifCB2ODDoJJNq\26rZnnjZY51dHl?NU\ORXpYOjF5OEizOFM>
U87 NYnOfJZ6SXCxcITvd4l{KEG|c3H5NEHBS28zPSEQvHevcWw>M2TDR|I1NzR6IHi=NVTSV29NcW6mdXPld{BieG:ydH;zbZMh[XRiNEigbEB{cWewaX\pZ4FvfGy7MoXJNlE4QDh|NEO=
U251MmHZSpVv[3Srb36gRZN{[Xl?MWSwMVI2KM7:Zz;tUC=>M{C2clEzKGkEoB?=NU\xbmRZcW6mdXPld{BifXSxcHjh[5kh\G:|ZTDk[ZBmdmSnboTsfS=>Mn3hNlE4QDh|NEO=
U87 NEKwVJdHfW6ldHnvckBCe3OjeR?=MVGwMVI2KM7:Zz;tUC=>M1WxflEzKGkEoB?=MWrpcoR2[2W|IHH1eI9xcGGpeTDkc5NmKGSncHXu[IVvfGy7M1nXbFIyPzh6M{Sz
U87MGMUfGeY5kfGmxbjDBd5NigQ>?M2e1clAvOS9zL{GwJO69VQ>?NYPoXpVtOjRiaB?=MVPpcZBicXK|IITo[UBi\Ginc3nvckBw\iClZXzsd{B1dyC4aYTyc45m[3SrbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=MXmxPVIzOTF5MR?=
LN-308MUjGeY5kfGmxbjDBd5NigQ>?NHzVemYxNjFxMT:xNEDPxE1?MV:yOEBpMn62bY1x[Wm{czD0bIUh[WSqZYPpc44hd2ZiY3XscJMhfG9idnn0do9v\WO2aX6gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=MmjvNVkzOjFzN{G=
LN-18NHXNZ5hHfW6ldHnvckBCe3OjeR?=NH3wXokxNjFxMT:xNEDPxE1?M3\iZlI1KGh?M{XNd4lueGGrcoOgeIhmKGGmaHXzbY9vKG:oIHPlcIx{KHSxII\peJJwdmWldHnuJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXyMWSxPVIzOTF5MR?=
T98GNVnlcWxPTnWwY4Tpc44hSXO|YYm=MXmwMlEwOS9zMDFOwG0>MWSyOEBpMmfobY1x[Wm{czD0bIUh[WSqZYPpc44hd2ZiY3XscJMhfG9idnn0do9v\WO2aX6gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=M{XVdFE6OjJzMUex
LNT-229 NH;sbIRHfW6ldHnvckBCe3OjeR?=M3TNblAvOS9zL{GwJO69VQ>?MYGyOEBpMVrpcZBicXK|IITo[UBi\Ginc3nvckBw\iClZXzsd{B1dyC4aYTyc45m[3SrbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=NIDMeYMyQTJ{MUG3NS=>
HMEC-1 NELOfXJHfW6ldHnvckBCe3OjeR?=MmrhNU82NzVyIN88[{9udA>?Mo\uNlQhcA>?NUPVTGRDcW6mdXPld{BiKGSxc3Wg[IVx\W6mZX70JIRmfGGlaH3lcpTDqA>?NX;oUYx7OTlzMUSwNFU>
HMEC-1 MnfUVJJwdGmoZYLheIlwdiCDc4PhfS=>MUSxM|UwPTBizsznM41tNFfid28zPC92OD:3NkBpMUHpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzMWGxPVEyPDByNR?=
HMEC-1 NGC5VGJCeG:ydH;zbZMhSXO|YYm=MX2xM|UwPTBizsznM41tM4m0RlI1KGh?M3;mN4lv\HWlZYOgZZBweHSxc3nzNVS0WodYOTlzMUSwNFU>
G28NYD5XJhNWHKxbHnm[ZJifGmxbjDBd5NigQ>?MoPCNU82NzVyIN88[{9udA>?MWSyOE81QC95MjDoNFvNcJBqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{NVT2O441OTlzMUSwNFU>
G44M1vySnBzd2yrZnXyZZRqd25iQYPzZZk>NV7xTYJ5OS93L{WwJO69\y:vbB?=M{TidlI1NzR6L{eyJIg>MVzpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzMkfzNVkyOTRyMEW=
G28M2PnbWFxd3C2b4Ppd{BCe3OjeR?=MVOxM|UwPTBizsznM41tMWOyOEBpNU\uVnM4cW6mdXPld{BieG:ydH;zbZM>MljJNVkyOTRyMEW=
G44MV\BdI9xfG:|aYOgRZN{[Xl?MX2xM|UwPTBizsznM41tMnvKNlQhcA>?MnTFbY5lfWOnczDhdI9xfG:|aYO=M2TYc|E6OTF2MEC1
HMEC-1 NWTNT5JGTnWwY4Tpc44hSXO|YYm=MnfUNlAwPDBxNkCg{txoN22uMknabY5pcWKrdIOgSmFMKGGwZDDTdoPDqA>?NIH5fpQyQTFzNECwOS=>
G28M3HQUGZ2dmO2aX;uJGF{e2G7MYi1NEDPxGdxbXy=MWCzNE83OC9zMkCgcYlvMWfpcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gSmFMNCCVcnOgZY5lKEGtdB?=M2O0blE6OTF2MEC1

... Click to View More Cell Line Experimental Data

In vivo Cilengitide is activity against tumor growth and angiogenesis as single-agent. 100 μg Cilengitide induces a significant decrease in the number of CD 31+ vessels seen in tumors (2/high-power field) compared with control tumors (56/high-power field). 100 μg Cilengitide increases cellular apoptosis in the brain tumors of animals (2.2% apoptotic cells/high-power field) compared with those receiving the inactive peptide (1.7% cells/high-power field). Cilengitide treatment results in prolonged survival of the mice bearing melanoma xenografts M21 compared with control treatment group. (36.5 vs 17.3 days). [5] Cilengitide can augment the therapeutic benefit associated with cytotoxic agents including chemotherapy and radiation therapy in tumor models. Cilengitide (250 mg/dose) alone does not alter tumor growth of breast cancer xenografts when compared with untreated mice, but combined modality RIT (CMRIT) using RIT and six doses of Cilengitide (250 mg/dose) increases efficacy of treatment, with the cure rate for mice that receives only RIT increasing from 15 to 53%. CMRIT significantly increases apoptosis of tumor and endothelial cells 5 days, and decreases tumor proliferation. [6]
Features

Protocol(Only for Reference)

Kinase Assay: [2]

Integrin-binding competition assay Recombinant soluble integrins are immobilized, and peptides, which are serially diluted in Tris-buffered saline (TBS++) (0.1% (w/v) BSA, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2 10 μM MnCl2, 20 mM Tris-HCl; pH 7.4), are added in parallel with biotinylated vitronectin (to 1μg/mL). After a 3-h incubation at 37℃ and washing with Tris–buffered saline, bound ligand is detected by incubation with an antibiotin alkaline phosphatase-conjugated antibody (BioRad) followed by development with p-nitrophenyl phosphatase substrate. The reaction is stopped by the addition of NaOH and the color intensity read at 405 nm.

Cell Assay: [3]

Cell lines Human microvascular endothelial cell line HMEC-1
Concentrations 1-50 μg/mL
Incubation Time 3 days
Method HMEC-1 (1×104 per well) are seeded on uncoated 48 well plates and incubated in medium containing 4% FCS with Cilengitide. After incubation for 72 hours at 37℃, cells are trypsinized and counted.

Animal Study: [5]

Animal Models Human glioblastoma xenografts U87 MG
Formulation PBS
Dosages 100μg
Administration Daily i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Reardon DA, et al. Genes Cancer, 2011, 2(12):1159-1165.

[2] Nisato RE, et al. Angiogenesis, 2003, 6(2), 105-119.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-05-07)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01782976 Withdrawn Glioblastoma M.D. Anderson Cancer Center|Brain Tumor Trials Collaborat  ...more M.D. Anderson Cancer Center|Brain Tumor Trials Collaborative|EMD Serono June 2013 Phase 2
NCT01517776 Terminated Gliomas Martin-Luther-Universität Halle-Wittenberg|Merck KGaA January 2012 Phase 2
NCT01504165 Completed Renal Impairment Merck KGaA January 2012 Phase 1
NCT01276496 Completed Adult Solid Neoplasm|Estrogen Receptor Negative|HER2/Neu Negative|Male Breast Carcinoma|Progesterone Receptor Negative|Recurrent Breast Carcinoma|S  ...more Adult Solid Neoplasm|Estrogen Receptor Negative|HER2/Neu Negative|Male Breast Carcinoma|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma National Cancer Institute (NCI) December 2010 Phase 1
NCT01165333 Completed Diffuse Intrinsic Pontine Glioma Centre Oscar Lambret August 2010 Phase 1

view more

Chemical Information

Download Cilengitide SDF
Molecular Weight (MW) 702.68
Formula

C29H41F3N8O9

CAS No. 199807-35-7
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms EMD 121974, NSC 707544
Solubility (25°C) * In vitro DMSO 100 mg/mL (142.31 mM)
Water 8 mg/mL (11.38 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name Cyclo(L-arginylglycyl-L-α-aspartyl-D-phenylalanyl-N-methyl-L-valyl) 2,2,2-trifluoroacetic acid(1:1)

Customer Product Validation (3)


Click to enlarge
Rating
Source J Clin Invest, 2015, 125(5): 1886-900. Cilengitide purchased from Selleck
Method Immunostain Assay
Cell Lines WT mice liver
Concentrations 10 mg/kg
Incubation Time 6 d
Results Mice treated with cilengitide suffered impaired ductular reaction with greatly diminished CK19-positive area and reduced PCNA-positive proliferating cholangiocytes, indicating that engagement of integrins αvβ3 and αvβ5 is critical for ductular reaction.

Click to enlarge
Rating
Source J Clin Invest, 2015, 125(5): 1886-900. Cilengitide purchased from Selleck
Method Cell Proliferation Analysis
Cell Lines Cholangiocytes
Concentrations 1 µM
Incubation Time 2 d
Results CCN1 and JAG1 both enhanced DNA synthesis as judged by BrdU labeling, and CCN1-stimulated DNA synthesis was blocked by an inhibitor of NOTCH signaling (DAPT) or NF-κB activation (NBD peptide), and abrogated by cilengitide, a cyclic pentapeptide that blocks αvβ3 and αvβ5 integrins.

Click to enlarge
Rating
Source Dr.Milica Pesic from Institute for Biological Research . Cilengitide purchased from Selleck
Method MTT
Cell Lines HTB 183, A549
Concentrations 0-50 uM
Incubation Time 72 h
Results Cell growth inhibition of non-small cell lung carcinoma (NSCLC) by Cilengitide.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Integrin Products

Recently Viewed Items

Tags: buy Cilengitide | Cilengitide supplier | purchase Cilengitide | Cilengitide cost | Cilengitide manufacturer | order Cilengitide | Cilengitide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us